GSK acquires "potential best-in-class" medicine efimosfermin

(Alliance News) - GSK announced on Wednesday that it has agreed with Boston Pharmaceuticals to ...

Alliance News 14 May, 2025 | 8:13AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GSK announced on Wednesday that it has agreed with Boston Pharmaceuticals to buy steatotic liver disease medication efimosfermin alfa.

The London-based pharmaceutical company said efimosfermin, Boston Pharmaceuticals' lead asset, is a "[phase 3]-ready, potential best-in-class, investigational specialty medicine" for the treatment and prevention of steatotic liver disease.

GSK said it will pay USD1.2 billion upfront for efimosfermin, with the potential for a further USD800 million aggregate in additional success-based milestone payments.

The company said efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of two forms of SLD: metabolic dysfunction-associated steatohepatitis or MASH, including cirrhosis, and future development in alcohol-related liver disease or ALD.

GSK added that SLD represents an area of significant unmet medical need with limited therapeutic options for patients, who make up approximately 5% of the global population.

Furthermore, GSK said that recent phase 2 trial data for efimosfermin showed that monthly subcutaneous doses of efimosfermin rapidly and significantly reversed liver fibrosis and stopped its progression, with a manageable tolerability profile, in patients with biopsy-confirmed moderate-to-advanced MASH.

"The FGF21 class has shown some of the most exciting data in MASH including first-in-disease evidence of cirrhosis reversal, and efimosfermin has the potential to define a new standard-of-care with its monthly dosing and tolerability profile," commented Chief Scientific Officer Tony Wood. "Efimosfermin will significantly expand our hepatology pipeline and provide us the opportunity to develop a new potential best-in-class medicine with first launch expected in 2029.

"It complements GSK'990, also in development for ALD and MASH, offering GSK options to develop both monotherapy and potential combinations to improve patient outcomes."

GSK shares were up 1.0% at 1,371.00 pence in London on Wednesday morning.

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GSK PLC 1,843.00 GBX -0.83

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures